Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia

• Published in: The Journal of neuroscience Vol. 36; no. 24; pp. 6514 - 6524
• Main Authors: Figge, David A, Eskow Jaunarajs, Karen L, Standaert, David G
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 15.06.2016
• Subjects: Analysis of Variance; Animals; Antiparkinson Agents - adverse effects; Corpus Striatum - metabolism; Dioxygenases - metabolism; Disease Models, Animal; DNA Methylation - drug effects; Dopamine - metabolism; Dyskinesia, Drug-Induced - metabolism; Enzyme Inhibitors - pharmacology; GADD45 Proteins; Gene Expression Regulation - drug effects; Gene Expression Regulation - genetics; Immunoprecipitation; Intracellular Signaling Peptides and Proteins - metabolism; Levodopa - adverse effects; Male; Medial Forebrain Bundle - drug effects; Oxidopamine - toxicity; Parkinson Disease; Parkinson Disease, Secondary - chemically induced; Parkinson Disease, Secondary - drug therapy; Phthalimides - pharmacology; Rats; Rats, Sprague-Dawley; Tryptophan - analogs & derivatives; Tryptophan - pharmacology; DNA methylation; l-DOPA; dyskinesia

Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neuro...